Long COVID treatment without medication: how we approach post-COVID

To this day there is no approved drug for post-COVID syndrome that treats the condition itself. What gets prescribed targets single symptoms: sleeping pills for sleep, beta-blockers for the racing heart, antidepressants for mood, painkillers for pain. Each can make sense in an individual case, but many patients end up on four or five products that interact with each other while the underlying dysregulation is never addressed. The living systematic review in the BMJ (Zeraatkar 2024) confirms this gap: for hardly any drug intervention in long COVID is there robust evidence of efficacy.

Our aim is therefore different: whatever has stopped working, a network, a rhythm, a regulatory loop, we want to bring back into order, as far as possible without drugs. "Without medication" does not mean "against medication": we never change existing medication without your treating physicians. It means that we rely first on measurement, neuromodulation, regulation and training, and leave drugs where they are genuinely needed. The goal is not a lab value but a life with high quality of life.

Long COVID is not a single disorder but an imbalance across several systems that reinforce each other. In the brain, EEG studies after COVID-19 frequently show an increase in slow waves and altered network activity that correlates with the cognitive complaints, the brain fog (Cecchetti 2022; Silva-Passadouro 2024). In the autonomic nervous system, heart-rate-variability measurements show a sympathetic excess in many patients: the body is on permanent alert while the reserves are empty (Mooren 2023). At the cellular level, persistent neuroinflammation with activated microglia has been described, even after mild infections (Fernández-Castañeda 2022).

And in the vascular system, research follows a trail that the Douwes Brain Center’s parent clinic, Clinicum St. Georg, has been pursuing for years: fibrin-amyloid microclots and an endothelial dysfunction that may impair oxygen delivery in the finest vessels. Prof. Etheresia Pretorius described these microclots in the blood of long COVID patients (Pretorius 2022); in Germany, Dr. Beate Jaeger proposed H.E.L.P. apheresis as a possible approach (Jaeger 2022). We call it what it is: an important research direction, and not yet a proven therapy. More on the full picture on the page Long COVID & post-COVID.

We do not treat the label "post-COVID" but your measured profile. That is why every treatment begins with a structured assessment in our diagnostics: history, existing findings, questionnaires, clinical examination. Depending on the question, building blocks are added that otherwise stay scattered across many practices:

• qEEG network profile: 19 channels compared with an age-normed database. We see whether your processing is slowed (more theta, less alpha), whether networks are over-activated and exactly where, the basis for any neuromodulation.
• Autonomic testing: heart-rate variability at rest and under load, plus an orthostatic test. This lets us identify the sympathetic excess and POTS-like patterns objectively instead of assuming them.
• Labs: inflammation and coagulation markers, micronutrients, thyroid, blood count, to find treatable contributing causes and to rule out other conditions.
• Clinical assessments: standardised questionnaires on fatigue, cognition, sleep and mood. They make the course comparable later on.
• Pacing history: when does your system tip? How long does recovery take? What load is still possible right now? These questions decide the pace of the whole program.

A physician brings these findings together into one picture and discusses it with you. Only then do we decide which building blocks make sense.

From the profile we build an individual, energy-sparing program. Neuromodulation is one building block in it: immune activation that continues after the infection keeps inflammatory messengers in circulation, which dampen brain networks and the vagal brake alike. That is why lab work, sleep, gut and, where there are indications, infection work-up belong in the same plan as the stimulation. The building blocks, ordered by the question "what is out of balance in you?":

• Autonomic imbalance → taVNS. Gentle vagus-nerve stimulation at the ear is often the first building block in post-COVID. In the randomised COVIVA pilot trial, fatigue improved under active stimulation (Gierthmuehlen 2026); a further pilot study reports improvements in dysautonomia and cognition (Azabou 2026). Sessions are short, low in discomfort and can be continued at home after instruction.
• Brain fog and cognitive fatigue → tDCS and rTMS. Both stimulate the prefrontal cortex, which works slowed in long COVID. For tDCS there are two randomised, double-blind trials showing improved fatigue (Oliver-Mas 2023; Mischke 2026); for rTMS a Japanese study with improved fatigue and cognition (Sasaki 2023) and a sham-controlled case series (Sakib 2024). The evidence is growing, not complete, which is why we measure the course alongside.
• Unstable rhythm → neurofeedback. Trains the pattern measured in the qEEG towards the normal range, slowly, but without side effects.
• Energy budget → photobiomodulation and infusions. Red and near-infrared light for mitochondrial support showed benefits in post-COVID brain fog in a randomised sham-controlled pilot trial (Lim 2026). Micronutrient infusions are added individually according to lab findings.
• Signs of microclots → H.E.L.P. apheresis at Clinicum St. Georg. For selected patients with evidence of microclots and endothelial dysfunction, H.E.L.P. apheresis is available as an option at our parent clinic. We weigh it medically and openly name it as a research direction: a 2023 Cochrane review found no completed randomised trial yet (Fox 2023).

Neuromodulation opens a window. Whether it is used is decided by everyday life, and in post-COVID one rule applies that many find hard: do not push through. Whoever "catches up" after a good day pays it back the next day in post-exertional malaise (PEM). A structured pacing protocol clearly reduced post-exertional symptom worsening in a longitudinal study (Parker 2023). That is why we rebuild load in small, measured steps, with sleep regulation, dosed physiotherapy and breathing work as the frame. What that looks like in practice is explained in Long COVID, fatigue and PEM.

At the end of the program we repeat qEEG and heart-rate variability and compare them with your baseline profile. That way you see what has objectively changed, and we adapt instead of simply continuing. The whole process with time frames is at our program.

The evidence for neuromodulation in post-COVID comes from small-to-medium randomised trials and pilot studies. It is growing but not complete; a systematic review on brain fog after long COVID summarises the interventions as promising but still insufficiently tested (Gorenshtein 2024). What studies show on average is our starting point; your measured profile decides where we begin. What is realistic is a step-by-step gain in clarity, resilience and sleep quality over weeks, not the disappearance of long COVID after one session. All procedures are used off-label in post-COVID; what that means is explained in Off-label treatment explained. The studies we rely on are linked on the page Long COVID & post-COVID and marked by evidence grade.